INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $5 | $6 | $8 | $7 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $3 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $17 | $0 | $0 |
| Operating Expenses | $7 | $25 | $10 | $9 |
| Operating Income | -$7 | -$25 | -$10 | -$9 |
| % Margin | – | – | -19,810% | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$6 | -$24 | -$10 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$24 | -$10 | -$9 |
| % Margin | – | – | -19,478% | – |
| EPS | -0.24 | -1.05 | -0.43 | -0.41 |
| % Growth | 77.1% | -144.2% | -4.9% | – |
| EPS Diluted | -0.24 | -1.05 | -0.43 | -0.41 |
| Weighted Avg Shares Out | 27 | 23 | 22 | 22 |
| Weighted Avg Shares Out Dil | 27 | 23 | 22 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$8 | -$10 | -$9 |
| % Margin | – | – | -19,810% | – |